We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Enzyme Adapted to Enhance Nerve Agent Detoxification Capacity

By LabMedica International staff writers
Posted on 23 May 2012
Researchers have used directed evolution of a human liver enzyme to enhance its capacity to detoxify the most threatening known G-type nerve agents. More...
The improved versions are promising candidates for preventative preexposure treatment as well as for postexposure detoxification.

Today, protection against toxic nerve agents relies primarily on physical barriers such as gas masks and protective suits that can easily be breached, explained Dr. Moshe Goldsmith of the Weizmann Institute of Science (Rehovot, Israel). Following exposure, people are treated with drugs that help with the symptoms but do not eliminate the nerve agent.

Dr. Goldsmith and Prof. Dan Tawfik, senior author of the study, hope to change this, relying on the principles of molecular evolution to produce a more efficient version of an enzyme that occurs naturally in the liver. Known as paraoxonase 1 (PON1), this enzyme was originally named for its ability to assist in the breakdown of the insecticide paraoxon. It is also involved in drug metabolism and detoxification.

PON1 normally does counteract G-type nerve agents, including sarin, tabun, soman, and cyclosarin, but not well enough. Prof. Tawfik's lab, at Weizmann Institute’s Department of Biological Chemistry, specializes in the technique of "directed enzyme evolution”, in which mutations are artificially introduced into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria to produce the enzymes used for testing.

The goal was to end up with enzymes capable of detoxifying G-type nerve agents before they could reach their target and cause harm. Enzymes that passed the initial test went on to further rounds of evolution and testing. After four rounds of evolution, PON1 variants were obtained that worked up to 340 times better than those produced previously did. Overall, the researchers reported that the adapted PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

“Both the raw materials and know-how of producing deadly nerve agents are available to people outside government or military institutions," said Dr. Goldsmith; "We hope that our work would provide a prophylactic drug that will effectively protect the medical, police, and other teams that will have to act in a contaminated area following such an attack, and would also provide these teams with a drug that could be administered on-site to intoxicated individuals to greatly improve their chances of survival."

More broadly, the findings, published April 20, 2012, in the Cell Press journal Chemistry and Biology, further show the power of laboratory evolution to reshape existing enzymes for a variety of uses.

Related Links:

Weizmann Institute of Science



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Laboratory Software
ArtelWare
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.